Compass Pathways, a biotechnology company dedicated to increasing access to evidence‑based mental health treatment, will host a virtual fireside chat with Patrick Trucchio, Managing Director of Equity Research at HC Wainwright, on July 14, 2025 at 8:00 AM ET. The live audio will be accessible through the “Events” page under the Investors section on the Compass website.
Health Technology Insights: Verdantas Acquires Independent Solutions to Expand in Western U.S.
A recording of the session will be available for 30 days after the event, enabling interested stakeholders to watch the discussion at their own convenience. Compass Pathways is committed to providing scalable innovation in mental health treatment and is most renowned for COMP360, its synthetic psilocybin treatment, which gained Breakthrough Therapy designation from the U.S. Food and Drug Administration and Innovative Licensing and Access Pathway designation in the UK for use in treatment-resistant depression.
Health Technology Insights: Wilma Empowers ABA Practices with New Patient Management Tools
Motivated by a vision to assist people not served by current treatments, the company is seeking to break through symptom control to sustainable patient outcomes. Information on investor access includes direct guidance and contact details for media and investor inquiries. This event provides a chance to hear more about Compass Pathways’ strategic vision, milestones on the horizon, and future commercial potential of COMP360.
Health Technology Insights: Transition of Promotional Activities for Allergen Immunotherapy Drug Actair in Japan
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
